血液透析患者能否从金黄色葡萄球菌疫苗中获益?
金黄色葡萄球菌血流感染对血液透析患者可能造成灾难性后果,但迄今疫苗研发未成功。既往诱导抗体的候选疫苗在临床试验中未能预防或减轻感染。新一代疫苗需诱导有效T细胞免疫,而透析患者存在T细胞缺陷,可能影响疫苗应答,亟需了解该人群T细胞免疫。
要点
- 既往诱导抗体的金黄色葡萄球菌疫苗临床试验未能预防或减轻感染。
- 新一代疫苗需同时诱导有效T细胞介导的免疫。
- 透析患者存在T细胞缺陷,可能影响疫苗应答,需专门研究。
核心结论
- 有效的金黄色葡萄球菌疫苗需诱导T细胞介导的免疫,但透析患者的T细胞缺陷可能影响疫苗应答,亟需了解该人群的免疫特征。
研究设计与样本
- 本文为综述/评论性文章,未报告系统检索范围或样本量。
主要发现
- 既往诱导抗体的候选疫苗在临床试验中未能预防或减轻金黄色葡萄球菌感染。
- T-helper cell 1和T-helper cell 17在协调有效吞噬应答中起关键作用,通过细胞因子产生间接导致病原体破坏。
- 血液透析患者为免疫受损人群,存在特定T细胞缺陷,包括T-helper细胞亚群缺陷。
临床怎么用
- 临床应关注透析患者免疫受损状态对疫苗应答的潜在影响,并推动针对该人群的T细胞免疫研究。
局限性
- 原文未报告系统检索范围、样本量或具体研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Staphylococcus aureus bloodstream infection can have potentially catastrophic consequences for patients on hemodialysis. Consequently, an effective vaccine to prevent S aureus infection would have a significant influence on morbidity and mortality in this group. To date, however, efforts to develop a vaccine have been unsuccessful. Previous antibody-inducing vaccine candidates did not prevent or attenuate S aureus infection in clinical trials. Recent advances have helped to elucidate the role of specific T-cell subsets, notably T-helper cell 1 and T-helper cell 17, in the immune response to S aureus. These cells are essential for coordinating an effective phagocytic response via cytokine production, indirectly leading to destruction of the organism. It is now widely accepted that next-generation S aureus vaccines must also induce effective T-cell-mediated immunity. However, there remains a gap in our knowledge: how will an S aureus vaccine drive these responses in those patients most at risk? Given that patients on hemodialysis are an immunocompromised population, in particular with specific T-cell defects, including defects in T-helper cell subsets, this is likely to affect their ability to respond to an S aureus vaccine. We urgently need a better understanding of T-cell-mediated immunity in this cohort if an efficacious vaccine is ever to be realized for these patients.
引用
- Connolly R, Denton MD, Humphreys H, et al. Would hemodialysis patients benefit from a Staphylococcus aureus vaccine? Kidney Int. 2019. PMID: 30691691. doi:10.1016/j.kint.2018.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。